Big news related to India’s indigenous corona vaccine Covaxin has come out. In the third phase trial data, it has proved to be 77.8 percent effective. This report has been submitted to the Central Government Committee on behalf of Bharat Biotech. It was reported in the morning that Bharat Biotech, which makes Covaxin, has shared the data of clinical trials from the third phase related to it with the Drug Controller General of India (DCGI).
After getting the data of the third phase, the Subject Expert Committee (SEC) had a meeting today on Tuesday. , this information has been handed over by Covaxin. The SEC has seen the data given by Bharat Biotech. But at the moment no acceptance or rejection has been given. In further processing, the SEC will hand over its data to DCGI.
Let us tell you that Covaxin was approved for emergency use about 5 months ago without the results of these trials. There were also a lot of controversies when the trial results were approved without approval.